Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen.

Background: Prostate cancer affects 1 in 6 men, and it is the second‑leading cause of cancer-related death in American men. Surgery is one of the main treatment modalities for prostate cancer, but it often results in incomplete resection margins or complete resection that leads to nerve damage and undesirable side effects. In the present work, we have developed a new bimodal tracer, NODAGA-sCy7.

Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.

The purpose of this study was to examine how the introduction of ibuprofen (IBU) affected tumor-targeting and biodistribution properties of Lu-labeled IBU-conjugated alpha-melanocyte-stimulating hormone peptides. The IBU was used as an albumin binder and conjugated to the DOTA-Lys moiety without or with a linker to yield DOTA-Lys(IBU)-GG-Nle-CycMSH {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Lys(IBU)-Gly-Gly-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH}, DOTA-Lys(Asp-IBU)-GGNle-CycMSH, DOTA-Lys(Asn-IBU)-GGNle-CycMSH, and DOTA-Lys(Dab-IBU)-GGNle-CycMSH peptides. Their melanocortin-receptor 1 (MC1R) binding affinities were determined on B16/F10 melanoma cells first.

Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.

Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads.

Tailored supercontinuum generation using genetic algorithm optimized Fourier domain pulse shaping.

We report the generation of a spectrally tailored supercontinuum using Fourier-domain pulse shaping of femtosecond pulses injected into a highly nonlinear fiber controlled by a genetic algorithm. User-selectable spectral enhancement is demonstrated over the 1550-2000-nm wavelength range, with the ability to both select a channel with target central wavelength and bandwidth in the range of 1-5 nm. The spectral enhancement factor relative to unshaped input pulses is typically ∼5-20 in the range 1550-1800 nm and increases for longer wavelengths, exceeding a factor of 160 around 2000 nm.